You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy
|
|---|---|
| Published in |
Antimicrobial Agents and Chemotherapy, May 2014
|
| DOI | 10.1128/aac.02664-14 |
| Pubmed ID | |
| Authors |
T. W. Felton, J. A. Roberts, T. P. Lodise, M. Van Guilder, E. Boselli, M. N. Neely, W. W. Hope |
| Abstract |
Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in critically ill patients. Considerable pharmacokinetic (PK) variability is observed in critically ill patients. By estimating an individual's PK, dosage optimization Bayesian estimation techniques can be used to calculate the appropriate piperacillin regimen to achieve desired drug exposure targets. The aim of this study was to establish a population PK model for piperacillin in critically ill patients and then analyze the performance of the model in the dose optimization software program BestDose. Linear, with estimated creatinine clearance and weight as covariates, Michaelis-Menten (MM) and parallel linear/MM structural models were fitted to the data from 146 critically ill patients with nosocomial infection. Piperacillin concentrations measured in the first dosing interval, from each of 8 additional individuals, combined with the population model were embedded into the dose optimization software. The impact of the number of observations was assessed. Precision was assessed by (i) the predicted piperacillin dosage and by (ii) linear regression of the observed-versus-predicted piperacillin concentrations from the second 24 h of treatment. We found that a linear clearance model with creatinine clearance and weight as covariates for drug clearance and volume of distribution, respectively, best described the observed data. When there were at least two observed piperacillin concentrations, the dose optimization software predicted a mean piperacillin dosage of 4.02 g in the 8 patients administered piperacillin doses of 4.00 g. Linear regression of the observed-versus-predicted piperacillin concentrations for 8 individuals after 24 h of piperacillin dosing demonstrated an r(2) of >0.89. In conclusion, for most critically ill patients, individualized piperacillin regimens delivering a target serum piperacillin concentration is achievable. Further validation of the dosage optimization software in a clinical trial is required. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 6 | 46% |
| United Kingdom | 1 | 8% |
| Unknown | 6 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 62% |
| Practitioners (doctors, other healthcare professionals) | 4 | 31% |
| Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| France | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 88 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 23% |
| Researcher | 15 | 16% |
| Student > Master | 11 | 12% |
| Student > Postgraduate | 9 | 10% |
| Other | 6 | 7% |
| Other | 18 | 20% |
| Unknown | 12 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 24% |
| Agricultural and Biological Sciences | 4 | 4% |
| Nursing and Health Professions | 3 | 3% |
| Chemistry | 3 | 3% |
| Other | 9 | 10% |
| Unknown | 14 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2023.
All research outputs
#2,070,512
of 25,374,647 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#898
of 15,579 outputs
Outputs of similar age
#20,357
of 241,899 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#14
of 217 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 15,579 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,899 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 217 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.